EPISODE · May 2, 2025 · 22 MIN
Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
from Docs Who Lift · host Docs Who Lift
TakeawaysMASH is a significant obesity-related complication.Semaglutide shows promise in treating MASH.Weight loss is crucial for improving liver health.Bariatric surgery remains the most effective treatment.The Essence trial indicates a 63% resolution of NASH.New medications are being developed for obesity treatment.Early intervention is key to preventing severe liver damage.Accessibility of medications is a major concern.Comparative studies are essential for evaluating new treatments.Future treatments may include innovative delivery methods.Chapters00:00 Introduction to MASH and Semaglutide Study04:29 Understanding Metabolic Dysfunction and Its Implications08:02 Essence Trial: Semaglutide's Impact on MASH12:58 Comparative Analysis of New Treatments for MASH17:30 The Future of Obesity Treatment and Drug AccessibilityJoin Vineyard - Dr. Spencer's online clinicSee the study Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
In this episode, Spencer and Karl discuss a recent study on semaglutide for treating metabolic dysfunction associated steatotic liver disease (MASH). They explore the implications of the study, the Essence trial, and the potential of new treatments for obesity and liver health. The conversation also touches on the importance of early treatment and the need for more accessible medication options.
NOW PLAYING
Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.